



# Meet the Expert



拝啓 新緑の候、先生方におかれましてはますますご清祥のこととお慶び申し上げます。

さて、この度HER2をテーマとした学術講演会を下記の日程にて開催する運びとなりました。特別講演としてDr.Mark Sliwowskiご講演いただく予定です。

先生方におかれましては日々ご診療・ご研究にとご多忙とは存じますが、是非ともご出席賜りますようお願い申し上げます。

敬具

5月吉日

財団法人 癌研究会 有明病院  
化学療法科・血液腫瘍科 畠 清彦

日 時 : 2010年7月1日(木) 13:00~14:30

場 所 : 財団法人 癌研究会 有明病院 1階 「吉田講堂」

東京都江東区有明 3-8-31 Tel. 03-3520-0111

Chair : 財団法人 癌研究会 有明病院 化学療法科・血液腫瘍科 畠 清彦

13:00~

## Special Lecture

### 『Targeting Activated HER2 in Solid Tumor』

Speaker : Dr.Mark Sliwowski

【Abstract】

Herceptin, in combination with chemotherapy, is regarded as the standard of care in the treatment of HER2-positive breast cancer and promising data are also emerging in gastric cancer. Unfortunately, some patients with metastatic breast cancer are observed to progress on HER2-directed therapies. To address this unmet clinical need, we are developing alternative monoclonal antibody therapies.

14:00 ~

## Discussion

【Profile : Dr.Mark Sliwowski】

Mark Sliwowski is currently a Staff Scientist in Oncology at Genentech, Inc. He received his B.S. from the University of Delaware and his Ph.D in biochemistry from North Carolina State University and was a post doctoral fellow in the laboratory of Dr. Theresa C. Stadtman in the Laboratory of Biochemistry, in the National Heart, Lung and Blood Institute at NIH, where he studied bacterial enzymes that require selenium for their catalytic activity. Dr.Sliwowski joined Genentech, Inc. in 1991 as a senior scientist and worked on a number of programs involving drugs directed against the human epidermal growth factor receptor family(also known as the HER or ErbB family). Herceptin®(Trastuzumab) and Tarceva™(erlotinib) are now approved and marketed, whereas pertuzumab and T-DM1 are currently in phase III clinical testing.

## ■ ■ 会場ご案内 ■ ■


### 【電車】



#### ◆りんかい線 国際展示場駅より徒歩 2分



#### ◆ゆりかもめ 有明駅より徒歩 1分



### 【お車】

